In the News
Boost for Alzheon’s targeted Alzheimer’s candidate
thepharmaletter.com
Neurodegenerative Treatments Build to a Tipping Point
Genetic Engineering & Biotechnology News (GEN)
Take A Pill For It! Approach to Alzheimer’s Disease
Bloomer Boomer
Press Releases
Alzheon Appoints Susan Flint as Vice President of Clinical Operations, Patrick Kesslak, PhD, as Vice President of Clinical Development & Medical Affairs, and Erwan de Naurois as Vice President of Finance
New Executives Will Support Completion of APOLLOE4 Phase 3 Trial Evaluating Oral Tablet ALZ-801 (Valiltramiprosate) and Expansion of Product Portfolio
Alzheon to Present ALZ-801 (Valiltramiprosate) Phase 3 Program Update and Industry-Leading Disease Modifying Effects from Phase 2 Trial in Patients with Early Alzheimer’s Disease at AD/PD and NDDS Scientific Conferences
New Results Position ALZ-801 Tablet to Potentially Become the First Oral Agent that Can Slow or Even Stop and Prevent Alzheimer’s Pathology in Patients and Healthy [...]
Alzheon Reports Industry-Leading Disease Modifying Effects from Phase 2 Biomarker Trial of Oral Tablet ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer’s Disease
29% Reduction in Plasma P-tau181, Core Biomarker of Alzheimer’s Pathology, Observed after 6 Months Treatment in Carriers of One or Two Copies of APOE4 Gene who Represent Two Thirds of Patients with Disease
Alzheon to Present at H.C. Wainwright Bioconnect Conference on January 10, 2022
Alzheon CEO Dr. Martin Tolar Will Provide Overview of Company Business and Update on Oral Anti-Amyloid ALZ-801 Phase 3 Program in Alzheimer’s Disease
Alzheon to Present New Data from Ongoing Phase 2 Biomarker Trial of ALZ-801 Oral Tablet at Clinical Trials in Alzheimer’s Disease (CTAD) Conference
Baseline Data in Early Alzheimer’s Disease Shows Significant Differences in CSF Biomarker Profiles Between APOE4/4 Homozygotes and APOE3/4 Heterozygotes Validating Patient Selection for APOLLOE4 Phase 3 Study with ALZ-801 Tablet
Alzheon to Present at H.C. Wainwright Annual Global Investment Conference on September 13, 2021
Alzheon CEO Dr. Martin Tolar Will Provide Overview of Company Business and Update on Oral Anti-Amyloid ALZ-801 Phase 3 Program in Alzheimer’s Disease